[144] ANI Pharmaceuticals, Inc. SEC Filing
ANI Pharmaceuticals (ANIP) filed a Form 144 notifying a proposed Rule 144 sale of 50,000 common shares to be handled by Morgan Stanley Smith Barney LLC on 08/12/2025 on the NASDAQ. The filing lists an aggregate market value of $4,303,590.00 and 21,699,636 shares outstanding, making the proposed sale roughly 0.23% of outstanding shares and implying an approximate price of $86.07 per share. The shares were reported as acquired the same day by stock option exercise from the issuer with cash payment. The filing reports no securities sold in the past three months. The extract does not include the filer identity or a dated signature in the provided content.
ANI Pharmaceuticals (ANIP) ha presentato un Modulo 144 che notifica una vendita proposta ai sensi della Regola 144 di 50,000 azioni ordinarie, che sarà gestita da Morgan Stanley Smith Barney LLC il 08/12/2025 sul NASDAQ. Il documento indica un valore di mercato aggregato di $4,303,590.00 e 21,699,636 azioni in circolazione, pertanto la vendita proposta rappresenta circa il 0.23% delle azioni in circolazione e implica un prezzo approssimativo di $86.07 per azione. Le azioni sono state riportate come acquisite lo stesso giorno tramite esercizio di opzioni su azioni dall'emittente con pagamento in contanti. Il documento segnala nessuna vendita di titoli negli ultimi tre mesi. L'estratto fornito non include l'identità del dichiarante né una firma datata nel contenuto fornito.
ANI Pharmaceuticals (ANIP) presentó un Formulario 144 notificando una venta propuesta bajo la Regla 144 de 50,000 acciones ordinarias, que será gestionada por Morgan Stanley Smith Barney LLC el 08/12/2025 en el NASDAQ. La presentación indica un valor de mercado agregado de $4,303,590.00 y 21,699,636 acciones en circulación, por lo que la venta propuesta equivale a aproximadamente el 0.23% de las acciones en circulación e implica un precio aproximado de $86.07 por acción. Se informa que las acciones fueron adquiridas el mismo día mediante ejercicio de opciones sobre acciones del emisor con pago en efectivo. La presentación informa de ninguna venta de valores en los últimos tres meses. El extracto proporcionado no incluye la identidad del presentante ni una firma fechada en el contenido facilitado.
ANI Pharmaceuticals (ANIP)는 NASDAQ에서 08/12/2025에 Morgan Stanley Smith Barney LLC가 처리할 예정인 규정 144에 따른 50,000 보통주의 매도 예정 사실을 통지하는 Form 144를 제출했습니다. 제출서에는 총 시가총액 $4,303,590.00과 21,699,636주가 발행되어 있어, 이번 매도는 발행주식의 약 0.23%에 해당하며 주당 약 $86.07의 가격을 암시합니다. 해당 주식은 발행사로부터 주식옵션 행사로 같은 날 취득되었으며 결제는 현금으로 이루어졌습니다. 제출서에는 지난 3개월간 판매된 증권 없음으로 보고되어 있습니다. 제공된 발췌문에는 제출자 신원이나 날짜가 기재된 서명이 포함되어 있지 않습니다.
ANI Pharmaceuticals (ANIP) a déposé un formulaire 144 notifiant une vente proposée en vertu de la Rule 144 de 50,000 actions ordinaires, qui sera traitée par Morgan Stanley Smith Barney LLC le 08/12/2025 sur le NASDAQ. Le dépôt indique une valeur de marché agrégée de $4,303,590.00 et 21,699,636 actions en circulation, faisant de la vente proposée environ 0.23% des actions en circulation et impliquant un prix approximatif de $86.07 par action. Les actions sont indiquées comme ayant été acquises le même jour par exercice d'options sur actions auprès de l'émetteur avec paiement en espèces. Le dépôt signale aucun titre vendu au cours des trois derniers mois. L'extrait fourni n'inclut pas l'identité du déclarant ni une signature datée.
ANI Pharmaceuticals (ANIP) reichte ein Formular 144 ein, das einen geplanten Verkauf gemäß Rule 144 von 50,000 Stammaktien ankündigt, der von Morgan Stanley Smith Barney LLC am 08/12/2025 an der NASDAQ abgewickelt werden soll. Die Einreichung nennt einen aggregierten Marktwert von $4,303,590.00 und 21,699,636 ausstehende Aktien, sodass der vorgeschlagene Verkauf rund 0.23% der ausstehenden Aktien entspricht und einen ungefähren Preis von $86.07 pro Aktie nahelegt. Die Aktien wurden dem Bericht zufolge am selben Tag durch Ausübung von Aktienoptionen vom Emittenten erworben und mit Bargeld bezahlt. Die Einreichung vermerkt keine Wertpapiere, die in den letzten drei Monaten verkauft wurden. Der vorgelegte Auszug enthält nicht die Identität des Einreichers noch eine datierte Unterschrift.
- Transaction details are explicit: 50,000 shares, aggregate value $4,303,590.00, broker identified as Morgan Stanley Smith Barney LLC
- Acquisition and payment are clear: shares acquired by stock option exercise on 08/12/2025 and paid in cash
- Filer identity is not provided in the supplied extract, limiting clarity on who is selling
- No dated signature or notice date shown in the provided content, reducing verification of the filing's execution
Insights
TL;DR: Routine Rule 144 notice for a 50,000-share proposed sale; appears immaterial to capital structure given numbers provided.
The Form 144 discloses a proposed sale of 50,000 common shares with an aggregate market value of $4,303,590.00 to be executed through Morgan Stanley Smith Barney LLC on 08/12/2025. With 21,699,636 shares outstanding, the notice represents approximately 0.23% of outstanding shares and implies an approximate per-share level of $86.07 based on the stated market value. The shares were acquired via stock option exercise on 08/12/2025 and paid for in cash. No sales in the prior three months are reported. Based solely on the filing extract, there is no clear indication of a material market impact.
TL;DR: Filing shows a disclosed proposed sale but lacks identifying signature and filer details in the provided extract, limiting governance signal.
The Form 144 provides transaction specifics (broker, share count, acquisition method, payment type, aggregate value, and sale date) but the provided content does not include the name of the person for whose account the securities are to be sold, nor a visible signature or date of notice. The form also includes the standard representation about material adverse information and trading-plan language, but no plan adoption date or signer is present in the extract. This omission reduces the ability to assess insider intent or governance context from the supplied text alone.
ANI Pharmaceuticals (ANIP) ha presentato un Modulo 144 che notifica una vendita proposta ai sensi della Regola 144 di 50,000 azioni ordinarie, che sarà gestita da Morgan Stanley Smith Barney LLC il 08/12/2025 sul NASDAQ. Il documento indica un valore di mercato aggregato di $4,303,590.00 e 21,699,636 azioni in circolazione, pertanto la vendita proposta rappresenta circa il 0.23% delle azioni in circolazione e implica un prezzo approssimativo di $86.07 per azione. Le azioni sono state riportate come acquisite lo stesso giorno tramite esercizio di opzioni su azioni dall'emittente con pagamento in contanti. Il documento segnala nessuna vendita di titoli negli ultimi tre mesi. L'estratto fornito non include l'identità del dichiarante né una firma datata nel contenuto fornito.
ANI Pharmaceuticals (ANIP) presentó un Formulario 144 notificando una venta propuesta bajo la Regla 144 de 50,000 acciones ordinarias, que será gestionada por Morgan Stanley Smith Barney LLC el 08/12/2025 en el NASDAQ. La presentación indica un valor de mercado agregado de $4,303,590.00 y 21,699,636 acciones en circulación, por lo que la venta propuesta equivale a aproximadamente el 0.23% de las acciones en circulación e implica un precio aproximado de $86.07 por acción. Se informa que las acciones fueron adquiridas el mismo día mediante ejercicio de opciones sobre acciones del emisor con pago en efectivo. La presentación informa de ninguna venta de valores en los últimos tres meses. El extracto proporcionado no incluye la identidad del presentante ni una firma fechada en el contenido facilitado.
ANI Pharmaceuticals (ANIP)는 NASDAQ에서 08/12/2025에 Morgan Stanley Smith Barney LLC가 처리할 예정인 규정 144에 따른 50,000 보통주의 매도 예정 사실을 통지하는 Form 144를 제출했습니다. 제출서에는 총 시가총액 $4,303,590.00과 21,699,636주가 발행되어 있어, 이번 매도는 발행주식의 약 0.23%에 해당하며 주당 약 $86.07의 가격을 암시합니다. 해당 주식은 발행사로부터 주식옵션 행사로 같은 날 취득되었으며 결제는 현금으로 이루어졌습니다. 제출서에는 지난 3개월간 판매된 증권 없음으로 보고되어 있습니다. 제공된 발췌문에는 제출자 신원이나 날짜가 기재된 서명이 포함되어 있지 않습니다.
ANI Pharmaceuticals (ANIP) a déposé un formulaire 144 notifiant une vente proposée en vertu de la Rule 144 de 50,000 actions ordinaires, qui sera traitée par Morgan Stanley Smith Barney LLC le 08/12/2025 sur le NASDAQ. Le dépôt indique une valeur de marché agrégée de $4,303,590.00 et 21,699,636 actions en circulation, faisant de la vente proposée environ 0.23% des actions en circulation et impliquant un prix approximatif de $86.07 par action. Les actions sont indiquées comme ayant été acquises le même jour par exercice d'options sur actions auprès de l'émetteur avec paiement en espèces. Le dépôt signale aucun titre vendu au cours des trois derniers mois. L'extrait fourni n'inclut pas l'identité du déclarant ni une signature datée.
ANI Pharmaceuticals (ANIP) reichte ein Formular 144 ein, das einen geplanten Verkauf gemäß Rule 144 von 50,000 Stammaktien ankündigt, der von Morgan Stanley Smith Barney LLC am 08/12/2025 an der NASDAQ abgewickelt werden soll. Die Einreichung nennt einen aggregierten Marktwert von $4,303,590.00 und 21,699,636 ausstehende Aktien, sodass der vorgeschlagene Verkauf rund 0.23% der ausstehenden Aktien entspricht und einen ungefähren Preis von $86.07 pro Aktie nahelegt. Die Aktien wurden dem Bericht zufolge am selben Tag durch Ausübung von Aktienoptionen vom Emittenten erworben und mit Bargeld bezahlt. Die Einreichung vermerkt keine Wertpapiere, die in den letzten drei Monaten verkauft wurden. Der vorgelegte Auszug enthält nicht die Identität des Einreichers noch eine datierte Unterschrift.
FAQ
What does the ANIP Form 144 disclose?
Who is the broker handling the proposed ANIP sale?
When is the proposed sale date for the ANIP shares?
How were the 50,000 ANIP shares acquired?
What portion of ANIP outstanding shares does this notice represent?
Does the filing show any securities sold in the past three months for ANIP?
Does the extract identify the seller or include a signature?
